Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer
In this study, we established an MC38 immunological memory mouse model by administering an anti-PD-L1 antibody and evaluating the detailed characteristics of the immune microenvironment including the T cell receptor (TCR) repertoire. In addition, we found that the memory mouse can be established by surgical resection of residual tumor following anti-PD-L1 antibody treatment with a success rate of > 40%. In this model, specific depletion of CD8 T cells revealed that they were responsible for the rejection of reinoculated MC38 cells. Analysis of the tumor microenvironment (TME) of memory mice using RNA-seq and flow ...
Source: Cancer Immunology, Immunotherapy - June 4, 2023 Category: Cancer & Oncology Source Type: research
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
ConclusionsAccording to our results, ICIs monotherapy and immune-based combinations were associated with higher risk of all-grade and grade 3 –4 hypertransaminasemia. Monitoring liver function should be recommended in cancer patients treated with ICIs monotherapy or immune-based combination, and in case of underlying liver disease, a careful risk–benefit assessment appears as a mandatory need. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 20, 2023 Category: Cancer & Oncology Source Type: research
PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-na ïve CRC patients
This study highlights the significance of PD-1 expression on tumor-infiltrating NK and NKT cells and its association with disease prognoses in CRC patients. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 20, 2023 Category: Cancer & Oncology Source Type: research
Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma
ConclusionMature TLSs were associated with an increased number of cytotoxic lymphocytes in draining LNs, a lower frequency of LN metastasis, and favorable outcomes. Mature TLSs may support antitumor immunity by lymphocyte activation. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 20, 2023 Category: Cancer & Oncology Source Type: research
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
(Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 20, 2023 Category: Cancer & Oncology Source Type: research
Correction to: Endosialin ‑positive tumor‑derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma
(Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 20, 2023 Category: Cancer & Oncology Source Type: research
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
ConclusionsThese findings suggest the clinical significance of pretreatment sPD-L1 as well as posttreatment sPD-1 and sPD-L1 in NSCLC patients treated with ICI monotherapy. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 16, 2023 Category: Cancer & Oncology Source Type: research
Correction to: IL ‑17A promotes fatty acid uptake through the IL‑17A/IL‑17RA/ p‑STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte‑rich microenvironment
(Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 15, 2023 Category: Cancer & Oncology Source Type: research
Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology
AbstractNeoantigen burden and CD8 T cell infiltrate are associated with clinical outcome in pancreatic ductal adenocarcinoma (PDAC). A shortcoming of many genetic models of PDAC is the lack of neoantigen burden and limited T cell infiltrate. The goal of the present study was to develop clinically relevant models of PDAC by inducing cancer neoantigens in KP2, a cell line derived from the KPC model of PDAC. KP2 was treated with oxaliplatin and olaparib (OXPARPi), and a resistant cell line was subsequently cloned to generate multiple genetically distinct cell lines (KP2-OXPARPi clones). Clones A and E are sensitive to immune ...
Source: Cancer Immunology, Immunotherapy - May 13, 2023 Category: Cancer & Oncology Source Type: research
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer
In this study, we identified Brachyury-derived epitopes that elicit antigen-specific and tumor-reactive CD4+ T cells that directly kill tumors. T cells recognizing Brachyury epitopes were present in patients with head and neck squamous cell carcinoma. Next, we focused on gemcitabine (GEM) as an immunoadjuvant to augment the efficacy of antitumor responses by T cells. Interestingly, GEM upregulated HLA class I and HLA-DR expression in tumor, followed by the upregulation of anti-tumor T cell responses. As tumoral PD-L1 expression was also augmented by GEM, PD-1/PD-L1 blockade and GEM synergistically enhanced the tumor-reacti...
Source: Cancer Immunology, Immunotherapy - May 12, 2023 Category: Cancer & Oncology Source Type: research
Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12
AbstractThere is strong evidence that chemotherapy can induce tumor necrosis which can be exploited for the targeted delivery of immuno-oncology agents into the tumor microenvironment (TME). We hypothesized that docetaxel, a chemotherapeutic agent that induces necrosis, in combination with the bifunctional molecule NHS-IL-12 (M9241), which delivers recombinant IL-12 through specific targeting of necrotic regions in the tumor, would provide a significant antitumor benefit in the poorly inflamed murine tumor model, EMT6 (breast), and in the moderately immune-infiltrated tumor model, MC38 (colorectal). Docetaxel, as monothera...
Source: Cancer Immunology, Immunotherapy - May 11, 2023 Category: Cancer & Oncology Source Type: research
Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia
AbstractAnti-PD-1 monotherapy had limited clinical efficacy in relapsed/refractory (r/r) AML patients with higher PD-1 and PD-L1 expression. Hence, we investigated the efficacy and safety of PD-1 inhibitor with DNA hypomethylating agent (HMA) + CAG regimen in patients who had failed prior AML therapy. In this phase 2, single-arm study, r/r AML patients received azacitidine or decitabine plus CAG regimen with tislelizumab. Primary endpoints were efficacy (objective response rate [ORR]) and safety. Secondary endpoints included overall survival (OS), event-free survival (EFS) and duration of response (DOR). Statistical a...
Source: Cancer Immunology, Immunotherapy - May 11, 2023 Category: Cancer & Oncology Source Type: research
Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing
ConclusionsThe regression formula constructed using three PBMC biomarkers is an inexpensive, rapid, and convenient method that shows clinically useful performance for the diagnosis of PDAC. It aids diagnoses and differential diagnoses of PDAC from pancreatic disease by lowering the FNR compared to CT.Clinical trial registration Clinical Research Information Service, KCT0004614 (08 January 2020). (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 10, 2023 Category: Cancer & Oncology Source Type: research
Correction to: CD33 BiTE ® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
(Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 8, 2023 Category: Cancer & Oncology Source Type: research
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune ‑related adverse events among cancer patients
(Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - May 8, 2023 Category: Cancer & Oncology Source Type: research